This work is licensed under a Creative Commons Attribution 4.0 International License.
Magainin B
General Information
DCTPep ID DCTPep00172
Peptide Name Magainin B
Sequence GIGKFLHAAKKFAKAFVAEIMNS
Sequence Length 23
UniProt ID Not available
PubChem CID Not available
Origin Xenopus laevis
Type Native peptide
Classification
ACP Tumor active peptide
Activity Information
| Cell Line | Disease | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|
| RPMI-8402 | Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia | IC50=12 µg/ml | Trypan blue assay | 72 h | 1 |
| U-937 | Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia | IC50=17 µg/ml | Trypan blue assay | 72 h | 1 |
| Raji | EBV-related Burkitt lymphoma; Burkitt lymphoma | IC50=23 µg/ml | Trypan blue assay | 72 h | 1 |
| SSKT-1 | Leukemia | IC50=27 µg/ml | Trypan blue assay | 72 h | 1 |
| Daudi | EBV-related Burkitt lymphoma; Burkitt lymphoma | IC50=28 µg/ml | Trypan blue assay | 72 h | 1 |
| MLA | Leukemia | IC50=30 µg/ml | Trypan blue assay | 72 h | 1 |
| CHP-100 | Ewing sarcoma | IC50=32 µg/ml | Trypan blue assay | 72 h | 1 |
| K562 | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia | IC50=32 µg/ml | Trypan blue assay | 72 h | 1 |
| MCF-7 | Invasive breast carcinoma of no special type | IC50=37 µg/ml | Trypan blue assay | 72 h | 1 |
| PC-3 | Prostate carcinoma | IC50=41 µg/ml | Trypan blue assay | 72 h | 1 |
| HeLa | Human papillomavirus-related endocervical adenocarcinoma | LD50=125 µg/ml | MTT assay | 24 h | Patent |
| BMKC | Skin carcinoma | LD50=130 µg/ml | MTT assay | 24 h | Patent |
| MCF-7 | Invasive breast carcinoma of no special type | LD50=22 µg/ml | MTT assay | 24 h | Patent |
| PC-3 | Prostate carcinoma | LD50=45 µg/ml | MTT assay | 24 h | Patent |
| NCI-H1299 | Lung large cell carcinoma | LD50=60 µg/ml | MTT assay | 24 h | Patent |
| SW480 | Colon adenocarcinoma | LD50=60 µg/ml | MTT assay | 24 h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism magainin 2 and synthetic analogues can rapidly and irreversibly lyse hematopoietic tumor and solid tumor
Structure Information
PDB ID Not available
Predicted Structure DCTPep00172
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C116H184N30O28S1
Absent amino acids CDPQRTWY
Theoretical pI 10.00
Acidic residues 1
Basic residues 5
Polar residues 4
Molecular weight (Average) 2478.98
Molecular weight (Monoisotopic) 2477.36
Common amino acids A
Net charge 4
Instability index (II) 10.56
Aliphatic index 85.22
Grand average of hydropathicity (GRAVY) 0.387
Half Life
30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Should not be visible by UV spectrophotometry.
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 1708887
Title Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation
Year 1990
Literature 2
Pubmed ID 2285300
Title Magainin analogs effective against pathogenic protozoa
Year 1990
Patent
Patent ID US2005/0209157A1
Patent Title Short bioactive peptides and methods for their use
Other Iinformation Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status: Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.